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Early-stage carcinogenesisAcquisition of death-resistance is critical in the evolution of neoplasia. Our aim was to model the early stages
of carcinogenesis by examining intracellular alterations in cells that have acquired apoptosis-resistance after
exposure to a complex genotoxin. We previously generated sub-populations of BJ-hTERT human diploid ﬁ-
broblasts, which have acquired death-resistance following exposure to hexavalent chromium [Cr(VI)], a
broad-spectrum genotoxicant. Long-term exposure to certain forms of Cr(VI) is associated with respiratory
carcinogenesis. Here, we report on the death-sensitivity of subclonal populations derived from clonogenic
survivors of BJ-hTERT cells treated with 5 μM Cr(VI) (DR1, DR2), or selected by dilution-based cloning with-
out treatment (CC1). Following Cr(VI) treatment, CC1 cells downregulated expression of the anti-apoptotic
protein Bcl-2 and exhibited extensive expression of cleaved caspase 3. In contrast, the DR cells exhibited
no cleaved caspase 3 expression and maintained expression of Bcl-2 following recovery from 24 h Cr(VI) ex-
posure. The DR cells also exhibited attenuated mitochondrial-membrane depolarization and mitochondrial
retention of cytochrome c and SMAC/DIABLO following Cr(VI) exposure. The DR cells exhibited less basal
mtDNA damage, as compared to CC1 cells, which correlates with intrinsic (non-induced) death-resistance.
Notably, there was no difference in p53 protein expression before or after treatment among all cell lines.
Taken together, our data suggest the presence of more resilient mitochondria in death-resistant cells, and
that death-resistance can be acquired in normal human cells early after genotoxin exposure. We postulate
that resistance to mitochondrial-mediated cell death and mitochondrial dysregulation may be an initial phe-
notypic alteration observed in early stage carcinogenesis.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Despite making huge strides in understanding the molecular basis
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l rights reserved.known about the earliest stages of carcinogenesis. It has been sug-
gested that genotoxic exposure is sufﬁcient to trigger a mutagenic
“initiation step” [1]. However, the causal and temporal relationships
between genotypic and phenotypic alterations, as well as the poten-
tial role of the cellular stress response in mediating or modulating
early stage carcinogenesis, are not clear. Following extensive genetic
damage by a genotoxicant, most normal cells will be eliminated from
the proliferating population by either apoptosis or terminal growth ar-
rest (TGA). This might constitute a selective pressure for expansion of
cells with the ability to survive after exposure to apoptogenic levels of
a DNA damaging agent; and may yield a precursor pool of cells from
which death-resistant variants, that aremore predisposed towards neo-
plastic evolution,may emerge. Escape from or resistance to apoptosis or
TGA seems to be a requirement for cells to achieve limitless replicative
potential, making acquisition of death-resistance one of the most criti-
cal characteristics attained by cancer cells [1].
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well known occupational human respiratory carcinogens [2]. These
compounds are classiﬁed by the International Agency for Research
on Cancer as group 1 human carcinogens [3,4], as they were encoun-
tered by workers in the chromium mining and smelting industry.
The intracellular metabolic reduction of Cr(VI) yields an array of
structural genetic lesions, including direct DNA damage in the form
of Cr(VI)-DNA adducts, DNA strand breaks and DNA crosslinks, as
well as potential indirect damage through generation of reactive ox-
ygen species (ROS) [5]. The damage disrupts cellular homeostasis
and triggers both apoptosis and TGA, which have been previously
established as the primary mode of Cr(VI)-induced cell death
[6–8]. These characteristics of Cr(VI)-induced damage, make it a use-
ful model genotoxin for investigating the balance between cell death
and survival.
Apoptosis is the best characterized mechanism of controlled cell
death. It occurs via two main pathways, the extrinsic/death
receptor-mediated pathway and the intrinsic/mitochondrial-mediated
pathway, the latter of which is found to be compromised in most
cancer cells [9–11]. Once triggered, signals from both pathways can
lead to the activation of a group of cysteine proteases known as cas-
pases, and the initiation of apoptotic cell death via cleavage of effec-
tor caspases (i.e. caspase 3) [9]. The mitochondria are critical
regulators of apoptosis, as they harbor apoptogenic factors such as
cytochrome c and the second mitochondria-derived activator of cas-
pases/direct IAP binding protein with low pI (SMAC/DIABLO) that
initiate cell death upon release [9]. Moreover, the mitochondria are
also the prime functional location of the apoptotic regulatory pro-
teins of the Bcl-2 family, some of which have been shown to prevent
apoptosis by inhibiting mitochondrial-membrane permeabilization
[12], cytochrome c release and caspase activation [13], as well as oxida-
tive stress-induced damage [14,15].
The mitochondria contain and maintain their own genetic materi-
al, mitochondrial DNA (mtDNA). Dysregulation of mitochondria-
controlled functions, such as apoptosis and energy metabolism, may
be related to mtDNA defects that affect the synthesis and function
of encoded electron transport chain protein subunits [16]. mtDNA
damage can occur at high frequencies, due to the elevated resident
levels of ROS produced by mitochondrial respiration, absence of his-
tones, and limited DNA repair mechanisms functioning within the mi-
tochondria [16,17]. Notably, excessive oxidative damage to the
mtDNA may be a trigger for apoptosis [16,18].
The goal of this study was to examine the phenotypic alterations
in cells that have acquired apoptosis-resistance as a result of an “ini-
tiating” genotoxin exposure. Previously, our lab has reported on a
population of Cr(VI)-resistant human ﬁbroblasts, B-5Cr cells, derived
from survivors of BJ-hTERT cells (stably transfected with human telo-
merase (hTERT)) exposed to 5 μM Cr(VI) [19]. To ensure that the ob-
served resistance to Cr(VI)-induced cell death was due to acquired
apoptosis-resistance and not a result of clonogenic selection pressure,
the B-5Cr cells, as well as untreated B-0Cr cells, were further sub-
cloned. The subclonal populations include the clonogenic control
cell line, CC1 (derived from B-0Cr), and the DR1 and DR2 cell lines de-
rived from the B-5Cr cells.
We tested the hypothesis that survival after an initiating geno-
toxic insult may involve the selection of cells with mitochondrial-
associated dysregulated apoptotic control, leading to death-
resistance. In this study, we investigated cleaved caspase 3 expression
following exposure to both Cr(VI) and cisplatin, Bcl-2 protein expres-
sion, mitochondrial-membrane depolarization, and the release of cy-
tochrome c and SMAC/DIABLO following exposure of normal and
death-resistant cells to Cr(VI). In addition, we evaluated mtDNA dam-
age and copy number before and after Cr(VI) exposure. Our
results show that resistance to apoptosis can be acquired in normal
diploid human cells following an apoptogenic exposure to a chemical
genotoxicant. These observations suggest that the acquisition ofresistance to mitochondrial-mediated cell death, and/or selection for
mitochondrial dysregulation, may contribute to the earliest stages of
carcinogenesis.
2. Materials and Methods
2.1. Cell lines and culture
Cr(VI) resistant ﬁbroblasts (B-5Cr) were derived from human
foreskin ﬁbroblasts transfected with the hTERT gene (BJ-hTERT;
Geron Corp.), and further subcloned into both clonogenic control
(death-sensitive) cell lines (CC1 from B-0Cr cells) and death-
resistant cell lines (DR1 and DR2 from B-5Cr cells), as previously de-
scribed [19]. All cell lines were maintained in Dulbecco's Modiﬁed
Eagle Medium (DMEM) (Invitrogen Corporation), containing Medi-
um 199 (Invitrogen Corporation), 10% fetal bovine serum (Hyclone
Laboratories, Inc.), 5 μg/ml gentamicin (Life Technologies), and
0.75 μg/ml fungizone antimycotic (Invitrogen Corporation). The
hTERT transgene was selected for by the addition of 10 μg/ml hygro-
mycin B (Life Science Technologies) to the medium. All cell lines were
incubated in a 95% air and 5% CO2 humidiﬁed atmosphere at 37 °C,
and the medium was replaced every 48 h.
2.2. Experimental treatment of cells
Sodium chromate [Cr(VI)] (Na2CrO4.4H2O, J.T. Baker Chemical
Co.) was dissolved and diluted in DMEM and sterilized by passage
through a 0.2 μm ﬁlter. Where indicated, some experiments in-
cluded a recovery period, in which Cr(VI) treated medium was re-
moved from cells, cells were rinsed with phosphate buffered
saline (PBS), and were incubated for 24 h in untreated DMEM.
For all experiments, cells were incubated at 37 °C for 24 h prior
to treatment.
2.3. Immunoblotting
Cells were seeded at a density of 4 X 105 cells/60 mm dish. Follow-
ing treatment, cells were scraped from the dish in CHAPS cell lysis
buffer (Cell Signaling Technology) supplemented with 50 mM NaF,
1 mM Na3V04, and 1 mM PMSF. The cells were lysed by freezing and
thawing. The lysates were centrifuged and immunoblotting was per-
formed as previously described [20]. Antibodies used were as follows:
cleaved caspase 3, Bcl-2 (Cell Signaling Technology), hTERT (Rock-
land), p53 (EMD), and Bax (Calbiochem). An antibody to β-actin
(Sigma-Aldrich) was used to conﬁrm equal protein loading.
2.4. Cr(VI)-DNA adducts
Cells were seeded at 8×105 cells/100 mm dish and treated with
Cr(VI) containing 5 μCi Na251CrO4/dish for 2 h, 24 h, or 24 h followed
by a 24 h recovery period in fresh DMEM. The cells were suspended
in lysis buffer (10 mM Tris–HCl, 0.5% SDS, 0.5% Triton X-100) contain-
ing proteinase K at 37 °C overnight. DNA was phenol:chloroform
extracted, precipitated, and quantiﬁed using a multi-purpose scintil-
lation counter LS 6500 (Beckman Coulter) and expressed as pmole
51Cr(VI)/μg DNA.
2.5. Immunoﬂuorescence
Cells were seeded at a density of 1.5×104/well in 8-well chamber
slides (Nunc International). Following treatment the cells were
stained with 500 nM MitoTracker Red CMXRos (Mitotracker; Molec-
ular Probes) for 10 min at 37 °C, and ﬁxed with 3.7% paraformalde-
hyde in DMEM for 20 min at room temperature (RT). The cells were
permeabilized with 0.1% Triton-X, and blocked with 1% BSA/1%
heat-inactivated FBS. The cells were incubated with cytochrome c
Fig. 1. DR cells are resistant to Cr(VI)-induced caspase 3-mediated apoptosis. CC1, DR1
and DR2 cells (a) were treatedwith 0 or 6 μMCr(VI) for 24 h, followed by a 24 h recovery
period in fresh DMEM. Total cell protein was extracted after the recovery period. Proteins
were separated by SDS-PAGE and cleaved caspase 3 expressionwas detected by immuno-
blotting at 17 and 19 kDa. The same amount of protein loading was conﬁrmed by immu-
noblotting for β-actin. The data are expressed as percent of respective control, in the
absence of Cr(VI) and are the mean +/− SE of four experiments. * indicates statistically
signiﬁcant difference from respective untreated control (pb0.05).
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Technology) for 1 h at RT. The slides were rinsed, blocked, and incu-
bated with goat anti-mouse IgG secondary antibody conjugated to
Alexa 488 (1:500) (Molecular Probes). Hoechst dye was used to indi-
cate the nucleus (1:1000) (Molecular Probes). The cells were visual-
ized at 63X using a Zeiss laser scanning microscope, at excitation
wavelengths of 543, 488, and 405 nm for MitoTracker, Alexa 488,
and Hoechst, respectively. Cells were individually analyzed using
Image-Pro Plus software (Media Cybernetics, Inc.). For each experi-
ment twenty cells per condition were analyzed. Segmentation analy-
sis was done to threshold the images with dynamic ranges of
approximately 30–255 (Red channel) and 40–255 (Green channel).
Pixel area was counted and measured for the selected cell in the spe-
ciﬁc dynamic ranges to analyze Red only, Green only, Green within
red, and Green outside of Red. Values for Green outside of Red were
normalized to Red only.
2.6. Mitochondrial DNA damage analysis
Cells were seeded at a density of 1×106/100 mm dish and incu-
bated at 37 °C for 24 h prior to treatment. Cells were treated with
0 or 6 μM Cr(VI) for 24 h, washed with PBS, trypsinized, and centri-
fuged at 1000 rpm for 5 min. DNA was extracted using a Qiagen
QIAamp DNA Mini Kit, according to the manufacturer's instructions
(Qiagen Incorporated). The DNA concentration and integrity were de-
termined, and mtDNA and nuclear DNA (nuDNA) copy number were
assessed by real-time polymerase chain reaction (RT-PCR) using SYBR
Green I Dye, AmpliTaq gold DNA polymerase (Applied Biosystems In-
corporated), and primers for the ampliﬁcation of mitochondrial
NADH dehydrogenase 1 (ND1) and the β2microglobulin (β2m) gene
to assess mtDNA and nuDNA, respectively. Cell copy number was
measured assuming diploid cells and calculated by dividing nuDNA
copy number by two. mtDNA damage was measured by the ampliﬁ-
cation of an 8.9-kb mtDNA target by quantitative PCR (QPCR) accord-
ing to a modiﬁcation of the method of Santos et al. [21]. mtDNA
damage was expressed as amount of 8.9-kb DNA/106 ND1 copies am-
pliﬁed, with ampliﬁcation being inversely proportional to mtDNA
damage.
2.7. Statistical analysis
To determine signiﬁcant differences among experimental groups,
statistical analyses were performed using GraphPad Prism version
4.00 as previously described [22].
3. Results
3.1. Resistance to genotoxin-induced caspase 3-mediated cell death ac-
quired after Cr(VI) exposure
To investigate relative death-sensitivity in our model system,
we assessed susceptibility to apoptosis. Cleavage of caspase 3
was measured after 24 h exposure to the apoptogenic concentra-
tion of 6 μM Cr(VI) followed by a 24 h recovery period (Fig. 1).
In the absence of Cr(VI) treatment, cleaved caspase 3 protein ex-
pression was undetectable in all of the cell lines. The CC1 cell
line exhibited a 73-fold increase in cleaved caspase 3 expression
after Cr(VI) treatment, as compared to the untreated control. In
sharp contrast, the DR1 and DR2 cell lines showed signiﬁcant re-
sistance to Cr(VI)-induced caspase 3 cleavage, which was only
9.5 and 11-fold of the untreated control, respectively. The
apoptosis-resistance observed in the DR cells was not Cr(VI)-spe-
ciﬁc: the BJ-hTERT parental cells exhibited a marked increase in
cleaved caspase 3 expression, which was 99 and 857-fold of con-
trol, respectively, after 3 h treatment with apoptogenic doses of
cisplatin (20 μM and 40 μM) followed by a 48 h cisplatin-freerecovery period. In contrast, the respective cisplatin-induced incre-
mental caspase 3 cleavage was sharply attenuated in the DR1 cells,
at just 56 and 169-fold of control (Supplemental Fig. 1). Notably,
our data show similar sensitivity to Cr(VI) in the BJ-hTERT and
CC1 cell lines (data not shown).
To determine whether the observed death-resistance was only
a consequence of decreased Cr(VI) uptake during the treatment,
we measured Cr(VI)-DNA adduct formation, which serves as a rig-
orous, dose-sensitive biomarker for Cr(VI) exposure and uptake.
There was no signiﬁcant difference among the cell lines in
Cr(VI)-DNA adduct formation after exposure to 6 μM Cr(VI),
which was approximately 0.6 and 2.9 pmol/μg DNA after 2 h
(Fig. 2a) and 24 h (Fig. 2b) exposure, respectively. The slight de-
crease in Cr(VI)-DNA adduct formation observed in both DR2
and CC1 cells following a 24 h recovery period is not statistically
signiﬁcant, and does not correlate with death sensitivity (Fig. 2b,
striped bars).
Apoptosis resistance in cancer cells has also been directly associat-
ed with the increased expression of Bcl-2 and/or the loss of Bax ex-
pression [23]. Therefore, we determined the protein expression
levels of Bcl-2 after 24 h treatment with 0, 6, or 9 μM Cr(VI) followed
by a 24 h recovery period, which temporally correlates with the ob-
served cleaved caspase 3-mediated apoptosis resistance to Cr(VI).
There was no signiﬁcant difference in the basal expression levels
among all cell lines. However, we observed a signiﬁcant, 2-fold de-
crease in Bcl-2 protein following recovery from Cr(VI) treatment in
the CC1 cells, which was not observed in the DR cells (Fig. 3). We
also determined the protein expression of Bax basally and after geno-
toxin exposure, but found no difference among DR and CC cell lines
(data not shown).
3.2. DR cells are uniquely resistant to mitochondrial-mediated apoptosis
after Cr(VI) exposure
To investigate the potential involvement of the death-receptor
pathway of apoptosis in our death-resistant cell model system, each
cell line was treated with or without 100 nM [24] of anti-Fas for
Fig. 2. DR cell resistance to Cr(VI)-induced cleaved caspase 3-mediated apoptosis is not
related to decreased Cr(VI)-DNA adduct formation. CC1, DR1 and DR2 cells were trea-
ted with 0 or 6 μM Cr(VI) radiolabeled with Na251CrO4 for (a) 2 h, or (b) 24 h (solid
bars) followed by a 24 h recovery period in fresh DMEM (hatched bars). DNA was iso-
lated by phenol:chloroform extraction. The samples were lysed and analyzed for intra-
cellular 51Cr using a multi-purpose scintillation counter. Data are mean +/− SE of 2
experiments done in triplicate and are expressed as picomole of 51Cr normalized to
μg of DNA.
Fig. 3. DR cells maintain Bcl-2 protein expression levels following post-Cr(VI) treat-
ment recovery. CC1, DR1 and DR2 cells were treated with 0, 6, or 9 μMCr(VI) for 24 h, fol-
lowed by a 24 h recovery period in fresh DMEM. Total cell protein was extracted after
recovery period. Proteinswere separated by SDS-PAGE and Bcl-2 expressionwas detected
by immunoblotting. The same amount of protein loading was conﬁrmed by immunoblot-
ting for β-actin. Data for 0 and 6 μM Cr(VI) exposure are mean +/− SE of three experi-
ments, while 9 μM Cr(VI) exposure data are mean +/− SE of two experiments. All data
are normalized to β-actin. * indicates a statistically signiﬁcant difference from respective
untreated control (pb0.05).
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pase 3 protein expression by immunobloting (Supplemental Fig. 2a).
Our data show that the Fas ligand-mediated death-receptor pathway
of apoptosis is not activated, as cleaved caspase 3 expression was not
observed in the cells studied. Additionally, we investigated the ex-
pression levels of caspase 8 in our model system. Caspase 8 is critical
for the activation of the death-receptor pathway of apoptosis and is
activated upon cleavage [25]. We show that there is no decrease in
caspase 8 expression after 24 h Cr(VI) treatment followed by a 24 h
recovery period among all cell lines (Supplemental Fig. 2b). These
data are in keeping with previous reports from other laboratories,
showing that ﬁbroblasts are resistant to death-receptor-mediated ap-
optosis [26,27].
The involvement of the mitochondrial-mediated pathway of ap-
optosis was assessed in the death-resistant cell model system, by
investigating the dissipation of the mitochondrial-membrane poten-
tial (Δψm), as well as the release of the apoptogenic factors, cyto-
chrome c and SMAC/DIABLO, from the mitochondrial inner
membrane space (IMS) into the cytoplasm. Previous data from our
lab using ﬂow cytometric analysis of the JC-9 Δψm dependent dye
show that BJ-hTERT parental cells exhibit dissipation of Δψm,
resulting in a signiﬁcant 1.7 and 4.9-fold increase in mitochondrial
membrane depolarization following 24 h treatment with 9 μM
Cr(VI) and 0.5 h treatment of 45 μM hydrogen peroxide (H2O2), re-
spectively. In sharp contrast, the DR1 cells were unaffected by either
treatment (Supplemental Fig. 3). In light of these data, we deter-
mined the effect of Cr(VI) on the release of cytochrome c and
SMAC/DIABLO from the mitochondrial IMS by immunoﬂuorescent
confocal microscopy.
As shown in Fig. 4a and b, cytochrome c in untreated CC1, DR1 and
DR2 cells was localized to the mitochondria, as evidenced by the ex-
clusive co-localization of the cytochrome c antibody with Mitotracker
(far right panel, merge). Exposure of the CC1 cells to 6 μM Cr(VI) for
24 h induced a respective 3.3-fold increase in the mitochondrial re-
lease of cytochrome c into the cytosol, as compared to control. In con-
trast, cytochrome c remained predominantly localized to the
mitochondria in the DR1 and DR2 cells following 24 h treatment
with 6 μM Cr(VI), with just a 1.8 and 1.4-fold increase in cytosolic re-
lease as compared to untreated control, respectively. Similar results
were observed when we measured the localization of SMAC/DIABLO
following genotoxin exposure (Fig. 5a and b). When untreated, the
CC1, DR1 and DR2 cells exhibited distinct mitochondrial localization
of SMAC/DIABLO, as indicated by its exclusive co-localization with
Mitotracker (far right panel, merge). However, following 6 μM
Cr(VI) treatment, the CC1 cells showed a signiﬁcant 11-fold increase
in the release of SMAC/DIABLO into the cytosol, as compared to re-
spective control and treated DR1 cells. Taken together, our data
show that after Cr(VI) treatment, the release of both cytochrome c
and SMAC/DIABLO was attenuated in the DR cells when compared
to the CC1 cells.
3.3. DR cells display less basal mtDNA damage
Several studies have shown that in response to certain DNA dam-
aging agents, mitochondrial biogenesis can be induced as a survival
mechanism in an effort to repopulate damaged cells with functional
mitochondria [28–32]. mtDNA content correlates with mitochondrial
quantity, therefore, we measured mtDNA content before and after
24 h exposure to 6 μM Cr(VI), and found no signiﬁcant difference
among the cell lines (Fig. 6a).
Loss of mitochondrial function, growth arrest, and apoptosis have
been correlated with mtDNA damage [33]. Therefore, to further in-
vestigate the stability and potential involvement of mtDNA in
death-resistance in our model system, we measured mtDNA damage
before and after Cr(VI) treatment (Fig. 6b). QPCR ampliﬁcation of a
primer designed to detect an 8.9-kb product along the circular
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Fig. 4. DR cells show no release of cytochrome c from the inner mitochondrial membrane space following Cr(VI) treatment. CC1, DR1and DR2 cells were treated with 6 μM Cr(VI) for 24 h.
After treatment, the cells were incubated with Mitotracker CMXRos, ﬁxed and incubated with mouse anti-cytochrome c antibody and Alexa 488-conjugated goat anti-mouse secondary
antibody, and DNA was stained with Hoechst. Cells were seeded on 8-well chamber slides prior to treatment. (a) Mitochondria – red; cytochrome c – green; nucleus– blue. All images
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ampliﬁcation is inversely proportional to mtDNA damage. Our data
suggest that there is no direct effect of Cr(VI) exposure on mtDNAdamage, as treatment caused no difference in mtDNA damage as com-
pared to the respective untreated control among all cell lines. Intrigu-
ingly, however, we found that the CC1 cells display 20.5% and 10.8%
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Fig. 5. DR cells showno release of SMAC/DIABLO following Cr(VI) treatment. CC1, DR1andDR2 cells were treatedwith 6 μMCr(VI) for 24 h. After treatment, the cells were incubatedwith
Mitotracker CMXRos, ﬁxed and incubated with mouse anti-SMAC/DIABLO antibody and Alexa 488-conjugated goat anti-mouse secondary antibody, and DNA was stained with Hoechst.
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Fig. 6. DR cells display no change in mtDNA copy number, but intrinsically less mtDNA
damage. CC1, DR1, and DR2 cells were treated with 0 or 6 μM Cr(VI) for 24 h. Total DNA
was extracted and quantiﬁed, (a) mtDNA and nuclear (nu) DNA copy number were de-
termined by RT-PCR. Primers were generated for the 108-bp mitochondrial-encoded
ND1 gene and an 89-bp β2 microglobulin (β2m) gene to assess mtDNA and nuDNA, re-
spectively. Values are averages of three determinations obtained in one RT-PCR run.
The copy number/cell was calculated by dividing nuDNA copy number by two (assum-
ing the cells were diploid). mtDNA copy number was expressed as mtDNA copies/cell.
(b) mtDNA damage was measured by the ampliﬁcation of an 8.9-kb mtDNA target by
QPCR. mtDNA damage was inversely proportional to amount of ampliﬁcation , and
was expressed as amount of 8.9-kb DNA/106 ND1 copies ampliﬁed. * indicates a statis-
tically signiﬁcant difference from CC1 cells, regardless of Cr(VI) treatment. Data are
mean +/− SE of three experiments (0 μM Cr(VI), p=0.0516; 6 μM Cr(VI) p=0.0430).
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copies of the ND1 gene, as compared to the DR1 and DR2 cells, respec-
tively. These data indicate that the DR1 cells have signiﬁcantly less in-
trinsic/steady-state mtDNA damage as compared to the CC1 cells,
while the DR2 cells exhibit a moderate difference in damage as com-
pared to the CC1 cells (Fig. 6a).
4. Discussion
The selection of cells with the ability to survive after exposure to
apoptogenic levels of a DNA damaging agent may yield a precursor
pool of cells fromwhich neoplastic variants can emerge [19]. The dys-
regulation of mitochondrial-mediated cellular mechanisms such as
apoptosis, are frequently observed in malignant tumors, thus
highlighting a potential connection between mitochondria, death-
resistance and carcinogenesis [28,30]. We postulate that survival
after genotoxic insult may involve the selection of cells with mito-
chondrial dysregulation, leading to death-resistance. Our data dem-
onstrate that the DR cells, as compared to the death-susceptible
cells, are resistant to mitochondrial-mediated apoptosis and display
differences in intrinsic mtDNA damage that correlate with death-
resistance. The results of the present study provide insight into the
possible role of mitochondrial dysregulation and apoptosis-
resistance in the mechanisms of early stage carcinogenesis.
The use of human diploid ﬁbroblasts in this study enables us to in-
vestigate the earliest genotoxin-induced events that may occur innormal cells, yielding a pro-survival phenotype. As part of the intri-
cate cellular microenvironmental milieu, ﬁbroblasts are associated
with pathological conditions such as ﬁbrosis and carcinogenesis, as
they affect the behavior of neighboring cells, and contribute to the
maintenance of the extracellular matrix [34,35].
Our model system was derived from survivors of Cr(VI)-treated,
immortalized human diploid ﬁbroblasts (BJ-hTERT). BJ-hTERT cells
were exposed to a single dose of Cr(VI), yielding 1% cell survival,
from which a population of surviving (B-5Cr) cells was expanded
[19]. The B-5Cr cells exhibited enhanced long term survival and
growth potential (also observed in the subclonal populations exam-
ined in the current study; Supplemental Fig. 4), resistance to apopto-
sis induction from a variety of stimuli (indicated by phosphtidlyserine
translocation), and a stable p53 response [19]. Of note, the resistant
phenotype of the B-5Cr cells diminished with time in cell culture.
This phenomenon was attributed to the effect of cumulative cell divi-
sions in culture and extensive expansion. Similar progressive pheno-
typic changes have been observed in human lung ﬁbroblasts [36].
Therefore, to ensure that the observed resistance to Cr(VI)-induced
cell death in the B-5Cr cells was due to acquired apoptosis-
resistance and not a result of clonogenic selection pressure, early pas-
sages of the B-5Cr cells, that still exhibited the pro-survival pheno-
type, were subcloned to establish the DR1 and DR2 cell lines used in
the present study. Untreated BJ-hTERT (B-0Cr) cells were also used
to derive the clonogenic control cell line, CC1.
It is critical to emphasize that the observed death-resistant pheno-
type in our model system is a consequence of a single toxic and gen-
otoxic exposure. In vitro models of cellular death-resistance
generated via long-term, chronic, and slowly escalating exposure
doses are advantageous when studying the role of altered transport
and intracellular pharmacodynamics in response to cellular genotoxic
stress [37–40]. However, our system is unique in that it models initial
molecular events that occur in a normal cell that survived a single,
acute, initiating genotoxic challenge. While the selection model in
this study was generated by Cr(VI) treatment, it also exhibits a
cross-resistance to the well-known chemotherapeutic agent, cisplat-
in, as well as to H2O2 (Supplemental Figs. 1 and 3). This is in contrast
to published reports where Cr(VI)-resistant cell models were gener-
ated and exhibit resistance only to Cr(VI) (reviewed in [41]). This un-
derlines the utility of our cell model to assess loss of therapeutic
efﬁcacy and toxicity of chemotherapeutic agents in cells exhibiting
the earliest hallmarks of cancer.
Disruption of mitochondrial-mediated apoptosis signaling in ma-
lignant tumors has been directly associated with the enhanced ex-
pression of Bcl-2 [23]. The requirement of Bcl-2 for resistance to
Cr(VI)-induced death has been highlighted in studies in SV40-
transformed lung epithelial cells (BEAS-2B) by Azad et al. [42]. Our
data are in keeping with these studies in that a maintenance of Bcl-
2 protein expression correlated with Cr(VI)-induced cleaved caspase
3-mediated death-resistance as compared to a signiﬁcant decrease
in protein expression in the death-sensitive cells (Fig. 3). Studies
have also shown a relationship between Bcl-2 degradation and
Cr(VI)-induced ROS production [14,43], however; this correlation
was not observed in our system. Moreover, it is generally accepted
that ROS are mediators of cellular damage, including mtDNA damage
and consequently mitochondrial function [44,45]. Along these lines, a
recent study by Indran et al. has demonstrated that the basal and en-
dogenous production of ROS in cancer cells can be reduced as a con-
sequence of hTERT overexpression and lead to the improvement of
mitochondrial function [45]. As the cells in our system are derived
from hTERT-immortalized ﬁbroblasts, and exhibit phenotypic alter-
ations suggestive of dysregulated mitochondrial-mediated cell death
signaling, we measured the levels of hTERT protein expression. How-
ever, we found no difference basally or after genotoxin exposure
among all cell lines, suggesting lack of TERT involvement in the ob-
served DR phenotype (Supplemental Fig. 5a).
271K.P. Nickens et al. / Biochimica et Biophysica Acta 1823 (2012) 264–272In an effort to further investigate the possible link between
mitochondrial-mediated apoptosis resistance, the observed pheno-
typic alterations, and a potential redox effect in our model system,
we assessed mtDNA damage in the cell lines before and after Cr(VI)
treatment. Our data were obtained by long-range QPCR ampliﬁcation
and analysis of an 8.9-kb mtDNA product that is inversely proportion-
al to mtDNA damage (Fig. 6b). Interestingly, we found no direct effect
of Cr(VI) on mtDNA damage among all cell lines studied. However, in
the absence of any Cr(VI) treatment, both DR1 and DR2 cells exhib-
ited less inherent mtDNA damage as compared to the CC1 cells. The
reduced levels of mtDNA damage observed in the DR cells uncover a
potentially striking intrinsic mechanism for resistance. These data
imply that the ability of a population of cells to maintain a more sta-
ble mitochondrial genome (or potentially enhanced ROS buffering ca-
pacity), may increase their ability to survive in the face of cellular
oxidative stress. Therefore, we investigated the possibility that the
DR cells may exhibit restricted generation of ROS, which would result
in lower reduced intrinsic mtDNA damage. However, we found no
difference in the basal levels of total cellular ROS, total cellular O2-,
or mitochondria-speciﬁc O2- among all cell lines (data not shown).
Similar results were reported in a study by Kulawiec et al., where
breast cancer cell lines containing mutated mtDNA, as compared to
wild-type cells containing undamaged mtDNA exhibited resistance
to etopside-induced apoptosis, but demonstrated no association
with increased ROS production [46]. Furthermore, the authors found
that mutated mtDNA leads to the constitutive activation of the
P13K/Akt pathway [46]. Further data from our laboratory show a sig-
niﬁcant induction of phosphorylated-Akt serine-473 protein expres-
sion following Cr(VI) genotoxic exposure in the DR1 cells, which
was downregulated in the BJ-hTERT cells (Supplemental Fig. 6). Of
note, constitutive activation of Akt1, by myristolated Akt transfection,
did not induce death-resistance in the BJ-hTERT cells (data not
shown), potentially pointing to a further link between mtDNA dysre-
gulation and death resistance in the DR1 cells, which exhibit decre-
mental basal levels of mtDNA damage, as compared to the control
cells.5. Conclusion
Here we focused on mitochondrial involvement in the “black box”
of early stage carcinogenesis and cellular death-resistance. Mitochon-
dria are heterogeneous in nature, varying in content from cell to cell,
and varying in genetic material frommitochondria to mitochondria. It
is known that changes in critical cellular functions (ie. oxidative phos-
phorylation) can result from damaged or mutated mtDNA, and it has
been hypothesized that these alterations correlate with tumorigene-
sis [47,48]. Therefore, our hypothesis is supported by the idea that a
selected pool of cells with an innately enhanced survival capacity
(ie. lower ROS production or enhanced ROS buffering capacity), may
support or lead to the generation of more robust mitochondria; and
in the face of subsequent oxidative stress, these cells and their dysre-
gulated mitochondria, are able to survive.
The present study provides evidence that resistance to
mitochondrial-mediated apoptosis, dysregulation of mitochondrial
associated proteins, and the stability of mtDNA, may be among the
ﬁrst phenotypic alterations observed in early stage carcinogenesis.
We demonstrate that heritable resistance to apoptosis, one of the
hallmarks of cancer, can be acquired in normal diploid human cells,
following a single toxic and genotoxic exposure [1]. If death-
resistant cells also harbor mutations, the inappropriate survival and
replication of such genomically unstable cells may predispose them
to neoplastic progression. Investigations into the potential role of mi-
tochondria in early stage carcinogenesis are critical to our understand-
ing of origins of tumor emergence and may implicate mitochondrial
dysregulation as a carcinogenic biomarker.Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.10.005.
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